FDA Clears Combo Drug Orkambi for Cystic FibrosisFDA Clears Combo Drug Orkambi for Cystic Fibrosis

Orkambi combines the approved drug ivacaftor (Kalydeco) with lumacaftor and is indicated for patients with CF aged 12 years and older with two copies of the F508del mutation. FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
More News: Cystic Fibrosis | Health